Navigation Links
Juventas Therapeutics Demonstrates JVS-100 Delivery to Patients with Heart Failure is Safe and Provides Clinical Benefit
Date:5/24/2011

CLEVELAND, May 24, 2011 /PRNewswire/ -- Juventas Therapeutics is a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease.  The Company's lead product, JVS-100, encodes Stromal cell-Derived Factor 1 (SDF-1) which has been shown to repair damaged tissue through recruitment of circulating stem cells to the site of injury, prevention of ongoing cell death and restoration of blood flow.  Juventas recently presented the results from its Phase I heart failure trial at the 14th Annual Meeting of the American Society of Gene and Cell Therapy.

The 17-person, open-label, dose-escalation study targeted New York Heart Association (NYHA) class III heart failure patients. Class III patients represent approximately a quarter of the 6 million heart failure patients in the United States and account for half of all heart failure hospital admissions.

"We wanted to target truly sick patients for whom there are currently no real therapeutic options," states Marc Penn, M.D., Ph.D., scientific founder and Chief Medical Officer for Juventas.  "These patients tend to have a rapidly deteriorating quality of life and the potential to provide clinical benefit is meaningful."

The clinical trial met its safety endpoints and JVS-100 was well-tolerated by all patients at all doses tested.  At four months post-treatment, patients in the targeted therapeutic dose range, are showing clinically-relevant and statistically-significant median improvements of 36 meters for 6 minute walk distance (6MWD) and 22 points in the Minnesota Living with Heart Failure Questionnaire (MLHFQ).  Nearly half of the patients improved a full NYHA heart class and, importantly, no patients worsened in heart class. Echocardiographs demonstrated that the patients' cardiac function stabilized with dose-dependent trends toward improvement in left ventricular end systolic volume (LVESV) and left ventricular ej
'/>"/>

SOURCE Juventas Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Juventas Therapeutics Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia
2. Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy
3. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
4. Nile Therapeutics to Transition to OTCQB Marketplace
5. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
6. InVivo Therapeutics and The Miami Project to Cure Paralysis Form Strategic Research Collaboration to Develop Novel Treatments for Spinal Cord Injuries
7. Talecris Biotherapeutics Announces Results of Annual Stockholders Meeting
8. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
9. Cell Therapeutics Retires 7.5% Convertible Senior Notes
10. Talecris Biotherapeutics Announces First Quarter 2011 Results
11. Nektar Therapeutics Reports First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 1000 balances – ... input on customers’ weighing needs and expertly narrows down ... of balances, scales or even terminals. , First, ... smallest weight (or select readability instead) and define the ... additional selection criteria narrows down the list to models ...
(Date:7/24/2014)... 2014   Cypher Genomics, Inc., the ... Adam Simpson as president and chief ... comprehensive annotation and interpretation of individual human genomes ... "Cypher,s technology has the potential to play a ... accuracy, optimizing therapeutic approaches and reducing adverse drug ...
(Date:7/23/2014)... Arab Emirates (UAE) (PRWEB) July 23, 2014 ... Century recently announced that its biobanking project, ... , Ph.D. to its growing Advisory Board. Scott ... very pleased to have Dr. Vaught onboard with Provia’s ... depth and expertise that Provia’s management team brings to ...
(Date:7/23/2014)... Dresden-Rossendorf (HZDR), the Vienna University of Technology and ... embedding nearly perfect semiconductor crystals into a silicon ... nanowires, very fast and multi-functional processing units can ... future. The research results will be published in ... are considered the cornerstone of future chip technology, ...
Breaking Biology Technology:Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4A crystal wedding in the nanocosmos 2
... NEOG ) announced today that despite obstacles ... revenues increased 11% to $27,840,000, a record third quarter ... $25,180,000. Year-to-date, nine-month revenues rose 17% in the current ... Year-to-date net income for the first nine ...
... Strengthen Expertise in Immunotherapy of CancerBETHESDA, Md., March ... ), a biopharmaceutical company developing novel, proprietary antibodies ... diseases, today announced the the appointment of Sir ... antibody advisory panel. Other members of the company,s ...
... Company estimates sales of pixantrone, if approved, could potentially ... Philips, President of Cell Therapeutics, Inc. (CTI) (NASDAQ and ... the 8th Annual WBBA Invest Northwest Conference on Wednesday, ... CTI,s pixantrone program for treatment of aggressive relapsed non-Hodgkin,s ...
Cached Biology Technology:Neogen Reports Record Third Quarter 2Neogen Reports Record Third Quarter 3Neogen Reports Record Third Quarter 4Neogen Reports Record Third Quarter 5Neogen Reports Record Third Quarter 6Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics 2Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics 3Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics 4Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics 5Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference 2Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference 3
(Date:7/24/2014)... the product of 3.5 billion years of evolutionary trial ... life. But it may be reaching a tipping point. ... analysis of data published in Science , an ... decline of animals is contributing to what appears to ... biological extinction event. , Since 1500, more than 320 ...
(Date:7/24/2014)... A multi-institutional team of researchers has developed a new ... safe, noninvasive method for assessing the function and properties ... to better diagnosis and treatment of gut diseases. ... irritable bowel syndrome and inflammatory bowel disease all occur ... effects in patients with diseases such as diabetes and ...
(Date:7/24/2014)... affect the connections between nerve cells and influence the ... of the brain that plays a significant role in ... of the study have been published in the journal ... active communication between nerve cells, known as neurons. For ... network where they constantly relay signals to one another. ...
Breaking Biology News(10 mins):Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3New imaging agent provides better picture of the gut 2A protein couple controls flow of information into the brain's memory center 2A protein couple controls flow of information into the brain's memory center 3A protein couple controls flow of information into the brain's memory center 4
... of chemists from the University of Valencia (UV) has ... amphora found among remains at Lixus, in Morocco, was ... inside the 2,000-year-old vessel, which could be fragments of ... of archaeologists from the UV discovered a sealed amphora ...
... Although they are present almost everywhere, on land ... the superphylum Planctomycetes-Verrucomicrobia-Chlamydiae, or PVC, have remained in ... about a decade ago. Scientists at the European ... discovered that these poorly-studied bacteria possess proteins thought ...
... The Genetics Society of America is pleased to announce ... for Professional Development in Genetics. These travel ... and international meetings or enroll in laboratory courses. ... DeLill Nasser (1929-2000), who was instrumental in promoting genetics ...
Cached Biology News:Chemical analyses uncover secrets of an ancient amphora 2Membrane-coat proteins: Bacteria have them too 2
... number is a new product number, ... number. If showing no availability yet, ... number (C6671) or contact customer service ... Surface area 148 cm 2 ...
BD BioCoat Fibronectin 150 mm Culture Dishes...
... Colorimetric Detection System is intended for use ... generated by an in-house validated in vitro ... of interest. • ... a hybridization capture assay designed to detect ...
... uses include large-scale colony-counting and plaque-lifting, microbial ... TM automated colony picking and gridding ... product number, created to easily match Cornings ... please order under the old Sigma-Aldrich number ...
Biology Products: